title: Anxiolytic-like action of neuropeptide Y: mediation by Y1 receptors in amygdala, and dissociation from food intake effects.
abstract: Evidence from animal and human studies suggests that neuropeptide Y (NPY) may be a potent endogenous anxiolytic. The anatomic structures mediating this action of the peptide remain unknown. Furthermore, in addition to its anxiolytic-like effects, intracerebroventricular administration of NPY induces food intake through hypothalamic mechanisms, making the anxiolytic-like action of the peptide more difficult to interpret. The purpose of this study was to examine the anatomic substrate for the effects of NPY on anxiety, and to characterize the NPY receptors mediating these effects. Intracerebroventricular injection of NPY produced increased food intake in free-feeding animals, and dose-dependent anticonflict/anxiolytic-like effects in an established animal model of anxiety, the Geller-Seifter punished responding test. In contrast, microinjection of NPY into the central nucleus of the amygdala did not increase food intake in free-feeding animals, did not affect unpunished lever pressing for food, but did reproduce the anticonflict/anxiolytic-like effect with high potency. The selective NPY-Y1 agonist, p[Leu31,Pro34]NPY was approximately equipotent with native NPY in the conflict paradigm, and markedly more potent than the Y2 agonist, NPY13-36. Intrastriatal injections had no effect on conflict behavior. Thus, activation of Y1 receptors in the central nucleus of the amygdala produces effects similar to established anxiolytics without affecting food intake, suggesting that Y1-receptors in the amygdala may be a substrate for anxiolytic actions of NPY.
authors.affiliation: Department of Neuropharmacology, Scripps Research Institute, La Jolla, California.
authors.forename: M
authors.initials: M
authors.lastname: Heilig
authors.forename: S
authors.initials: S
authors.lastname: McLeod
authors.forename: M
authors.initials: M
authors.lastname: Brot
authors.forename: S C
authors.initials: SC
authors.lastname: Heinrichs
authors.forename: F
authors.initials: F
authors.lastname: Menzaghi
authors.forename: G F
authors.initials: GF
authors.lastname: Koob
authors.forename: K T
authors.initials: KT
authors.lastname: Britton
mesh_terms: D000679:Amygdala / Q000187:drug effects*; D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology*; D001522:Behavior, Animal / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005247:Feeding Behavior / Q000187:drug effects*; D007276:Injections, Intraventricular; D008297:Male; D008845:Microinjections; D009478:Neuropeptide Y / Q000008:administration & dosage / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D017476:Receptors, Neuropeptide Y / Q000187:drug effects*
chemical_list: D014151:Anti-Anxiety Agents; D009478:Neuropeptide Y; D017476:Receptors, Neuropeptide Y